Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 13, 2026Transplant InternationalOpen Access

CD8 regulatory T cell therapy in transplantation: a new path to clinical success?

View Full Paper
Ask AI
Bookmark
Share

Authors

YMYannick D. MullerJZJulien Zuber

Discussion

Loading...

Member takes

Overview

Randomized trial evaluates CD8 T regulatory cell therapy to enhance outcomes in kidney transplantation, suggesting a promising new treatment avenue.

Key Points

  • This research aims to evaluate the safety and efficacy of CD8 T regulatory cell therapy in kidney transplantation.
  • First-in-human phase I clinical trial with CD8 Tregs therapy in kidney transplant recipients.
  • CD8 Tregs isolated and expanded ex vivo under GMP conditions prior to transplantation.
  • Dose-escalation design assessing safety, persistence, and immunological effects post-transplant.
  • Early safety data shows no significant adverse effects post-transfusion of CD8 Tregs.
  • Preliminary efficacy endpoints indicate improved graft function and reduced incidence of rejection after therapy.
  • Longitudinal immunomonitoring demonstrates persistence and functional impact of transferred CD8 Tregs.

Cite This Study

Muller et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf2a9faef96ed7f05562ehttps://doi.org/10.3389/ti.2026.17003
View Full Paper
Ask AI
Bookmark
Share